

Martin Ingelsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/223113/publications.pdf>

Version: 2024-02-01

156
papers

20,119
citations

22132

59
h-index

13365

130
g-index

167
all docs

167
docs citations

167
times ranked

27487
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013, 45, 1452-1458.	9.4	3,741
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
3	Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. <i>Nature Genetics</i> , 2018, 50, 1505-1513.	9.4	1,331
4	The Alzheimer's Disease-Associated Amyloid β -Protein Is an Antimicrobial Peptide. <i>PLoS ONE</i> , 2010, 5, e9505.	1.1	868
5	Rare coding variants in <i>PLCG2</i> , <i>ABI3</i> , and <i>TREM2</i> implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
6	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
7	Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. <i>Nature Genetics</i> , 2018, 50, 559-571.	9.4	356
8	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 509-516.	1.2	347
9	Alzheimer's disease pathology propagation by exosomes containing toxic amyloid-beta oligomers. <i>Acta Neuropathologica</i> , 2018, 136, 41-56.	3.9	334
10	Alpha-Synuclein Oligomers "Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders. <i>Frontiers in Neuroscience</i> , 2016, 10, 408.	1.4	288
11	High levels of AAV vector integration into CRISPR-induced DNA breaks. <i>Nature Communications</i> , 2019, 10, 4439.	5.8	257
12	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1180-1190.	0.4	254
13	Uniform polarity microtubule assemblies imaged in native brain tissue by second-harmonic generation microscopy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7081-7086.	3.3	253
14	Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. <i>Nature Genetics</i> , 2022, 54, 560-572.	9.4	250
15	Serial propagation of distinct strains of A β prions from Alzheimer's disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10323-10328.	3.3	247
16	In Vivo Seeding and Cross-Seeding of Localized Amyloidosis. <i>American Journal of Pathology</i> , 2015, 185, 834-846.	1.9	235
17	Family-Based Association between Alzheimer's Disease and Variants in <i>UBQLN1</i> . <i>New England Journal of Medicine</i> , 2005, 352, 884-894.	13.9	232
18	Extracellular Alpha-Synuclein Oligomers Modulate Synaptic Transmission and Impair LTP Via NMDA-Receptor Activation. <i>Journal of Neuroscience</i> , 2012, 32, 11750-11762.	1.7	228

#	ARTICLE	IF	CITATIONS
19	Genetic predisposition to mosaic Y chromosome loss in blood. <i>Nature</i> , 2019, 575, 652-657.	13.7	198
20	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
21	Human Astrocytes Transfer Aggregated Alpha-Synuclein via Tunneling Nanotubes. <i>Journal of Neuroscience</i> , 2017, 37, 11835-11853.	1.7	196
22	$\hat{\pm}$ -Synuclein strains target distinct brain regions and cell types. <i>Nature Neuroscience</i> , 2020, 23, 21-31.	7.1	195
23	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.4	179
24	Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. <i>Lancet</i> , The, 2019, 394, 2173-2183.	6.3	177
25	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.4	173
26	Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood Cells. <i>American Journal of Human Genetics</i> , 2012, 90, 217-228.	2.6	168
27	Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. <i>American Journal of Human Genetics</i> , 2016, 98, 1208-1219.	2.6	164
28	Smoking is associated with mosaic loss of chromosome Y. <i>Science</i> , 2015, 347, 81-83.	6.0	163
29	Expression of APP pathway mRNAs and proteins in Alzheimer's disease. <i>Brain Research</i> , 2007, 1161, 116-123.	1.1	159
30	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	1.1	155
31	Extensive uptake of $\hat{\pm}$ -synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. <i>Molecular and Cellular Neurosciences</i> , 2017, 82, 143-156.	1.0	152
32	The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of $\hat{\pm}$ -synuclein oligomers with distinct biochemical, morphological, and functional properties. <i>Free Radical Biology and Medicine</i> , 2011, 50, 428-437.	1.3	121
33	Rapid Progression from Mild Cognitive Impairment to Alzheimer's Disease in Subjects with Elevated Levels of Tau in Cerebrospinal Fluid and the ϵ /APOE ϵ 4 Genotype. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 458-464.	0.7	119
34	Immunotherapy targeting $\hat{\pm}$ -synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] $\hat{\pm}$ -synuclein mice. <i>Neurobiology of Disease</i> , 2014, 69, 134-143.	2.1	117
35	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 429-440.	2.3	116
36	The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. <i>Neuroscience Letters</i> , 2007, 427, 127-131.	1.0	112

#	ARTICLE	IF	CITATIONS
37	Structural heterogeneity and intersubject variability of A β in familial and sporadic Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E782-E791.	3.3	105
38	Plasma A β Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men. Archives of Neurology, 2008, 65, 256-63.	4.9	100
39	A β and tau prion-like activities decline with longevity in the Alzheimer's disease human brain. Science Translational Medicine, 2019, 11, .	5.8	96
40	Clinical and Neuropathological Features of the Arctic APP Gene Mutation Causing Early-Onset Alzheimer Disease. Archives of Neurology, 2008, 65, 499.	4.9	91
41	Identification of Low Molecular Weight Pyroglutamate A β Oligomers in Alzheimer Disease. Journal of Biological Chemistry, 2010, 285, 41517-41524.	1.6	91
42	Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families. Journal of Biological Chemistry, 2007, 282, 7825-7832.	1.6	89
43	Quantitative Interaction Proteomics of Neurodegenerative Disease Proteins. Cell Reports, 2015, 11, 1134-1146.	2.9	88
44	Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. Journal of Neural Transmission, 2010, 117, 85-96.	1.4	87
45	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	0.6	86
46	Large Aggregates Are the Major Soluble A β Species in AD Brain Fractionated with Density Gradient Ultracentrifugation. PLoS ONE, 2012, 7, e32014.	1.1	85
47	Quantification of the Brain Proteome in Alzheimer's Disease Using Multiplexed Mass Spectrometry. Journal of Proteome Research, 2014, 13, 2056-2068.	1.8	85
48	Stability of Proteins in Dried Blood Spot Biobanks. Molecular and Cellular Proteomics, 2017, 16, 1286-1296.	2.5	81
49	Crosstalk between astrocytes and microglia results in increased degradation of α -synuclein and amyloid- β aggregates. Journal of Neuroinflammation, 2021, 18, 124.	3.1	81
50	A highly insoluble state of A β similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiology of Aging, 2009, 30, 1393-1405.	1.5	79
51	Secretion and Uptake of α -Synuclein Via Extracellular Vesicles in Cultured Cells. Cellular and Molecular Neurobiology, 2018, 38, 1539-1550.	1.7	79
52	Monoclonal antibodies selective for α -synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α -synuclein transgenic mice with the disease-causing A30P mutation. Journal of Neurochemistry, 2013, 126, 131-144.	2.1	77
53	Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease. PLoS ONE, 2016, 11, e0150672.	1.1	77
54	Heparan Sulfate Accumulation with A β Deposits in Alzheimer's Disease and Tg2576 Mice is Contributed by Glial Cells. Brain Pathology, 2008, 18, 548-561.	2.1	71

#	ARTICLE	IF	CITATIONS
55	Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1223-1230.	1.2	68
56	Transcriptional and conformational changes of the tau molecule in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 150-157.	1.8	65
57	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. <i>Proteomics - Clinical Applications</i> , 2016, 10, 1242-1253.	0.8	64
58	Transcriptional Up-Regulation and Activation of Initiating Caspases in Experimental Glaucoma. <i>American Journal of Pathology</i> , 2005, 167, 673-681.	1.9	63
59	The amyloid- β^2 degradation pattern in plasma – A possible tool for clinical trials in Alzheimer's disease. <i>Neuroscience Letters</i> , 2014, 573, 7-12.	1.0	62
60	Aggregated Alpha-Synuclein Transfer Efficiently between Cultured Human Neuron-Like Cells and Localize to Lysosomes. <i>PLoS ONE</i> , 2016, 11, e0168700.	1.1	61
61	Antibodies against Alpha-Synuclein Reduce Oligomerization in Living Cells. <i>PLoS ONE</i> , 2011, 6, e27230.	1.1	61
62	Single molecule profiling of tau gene expression in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2007, 103, 1228-1236.	2.1	60
63	Shared genetic contribution to ischemic stroke and Alzheimer's disease. <i>Annals of Neurology</i> , 2016, 79, 739-747.	2.8	56
64	Binding of β -synuclein oligomers to Cx32 facilitates protein uptake and transfer in neurons and oligodendrocytes. <i>Acta Neuropathologica</i> , 2019, 138, 23-47.	3.9	56
65	Alpha-Synuclein and Chaperones in Dementia With Lewy Bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 1058-1066.	0.9	55
66	Clinical and biochemical correlates of insoluble β -synuclein in dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2006, 111, 101-108.	3.9	55
67	Coordinated Expression of Caspase 8, 3 and 7 mRNA in Temporal Cortex of Alzheimer Disease: Relationship to Formic Acid Extractable $A\beta^{242}$ Levels. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 508-515.	0.9	54
68	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 247-255.	1.2	54
69	Immune cells lacking Y chromosome show dysregulation of autosomal gene expression. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 4019-4033.	2.4	54
70	No Association between CALHM1 and Alzheimer's Disease Risk. <i>Cell</i> , 2008, 135, 993-994.	13.5	53
71	Interference from Heterophilic Antibodies in Amyloid- β^2 Oligomer ELISAs. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1295-1301.	1.2	53
72	β -Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 437-448.	1.7	53

#	ARTICLE	IF	CITATIONS
73	Antibodies against alpha-synuclein: tools and therapies. <i>Journal of Neurochemistry</i> , 2019, 150, 612-625.	2.1	53
74	Human Traumatic Brain Injury Results in Oligodendrocyte Death and Increases the Number of Oligodendrocyte Progenitor Cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 503-515.	0.9	51
75	Efficient clearance of A β 2 protofibrils in A β 2PP-transgenic mice treated with a brain-penetrating bifunctional antibody. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 49.	3.0	49
76	Immunotherapy targeting β -synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders. <i>Immunotherapy</i> , 2014, 6, 141-153.	1.0	48
77	Association study of cholesterol-related genes in Alzheimer's disease. <i>Neurogenetics</i> , 2007, 8, 179-188.	0.7	47
78	Mosaic loss of chromosome Y in leukocytes matters. <i>Nature Genetics</i> , 2019, 51, 4-7.	9.4	47
79	Longitudinal changes in the frequency of mosaic chromosome Y loss in peripheral blood cells of aging men varies profoundly between individuals. <i>European Journal of Human Genetics</i> , 2020, 28, 349-357.	1.4	47
80	Increased Release of Apolipoprotein E in Extracellular Vesicles Following Amyloid- β Protofibril Exposure of Neuroglial Co-Cultures. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 305-321.	1.2	44
81	No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer's disease brain. <i>Acta Neuropathologica</i> , 2006, 112, 439-449.	3.9	41
82	Increased Inflammatory Response in Cytomegalovirus Seropositive Patients with Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e96779.	1.1	41
83	High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 22.	3.0	39
84	Cellular Uptake of β -Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of β -Synuclein and Mediated via Fc γ 3 Receptors. <i>Cellular and Molecular Neurobiology</i> , 2017, 37, 121-131.	1.7	39
85	Astroglial tracer BU99008 detects multiple binding sites in Alzheimer's disease brain. <i>Molecular Psychiatry</i> , 2021, 26, 5833-5847.	4.1	39
86	The Arctic A β 2PP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated A β 2. <i>Acta Neuropathologica Communications</i> , 2013, 1, 60.	2.4	38
87	The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links β -synuclein causing rapid formation of stable oligomers. <i>Biochemical and Biophysical Research Communications</i> , 2009, 378, 872-876.	1.0	37
88	Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 367, 228-231.	1.0	36
89	Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. <i>Acta Neuropathologica</i> , 2007, 114, 471-479.	3.9	36
90	Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes. <i>Journal of Neuroinflammation</i> , 2017, 14, 241.	3.1	35

#	ARTICLE	IF	CITATIONS
91	The existence of A β 2 strains and their potential for driving phenotypic heterogeneity in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2021, 142, 17-39.	3.9	35
92	Early fine motor impairment and behavioral dysfunction in (Thy1) ^{ΔE4} [A30P] alpha-synuclein mice. <i>Brain and Behavior</i> , 2018, 8, e00915.	1.0	34
93	Dual-task tests discriminate between dementia, mild cognitive impairment, subjective cognitive impairment, and healthy controls – a cross-sectional cohort study. <i>BMC Geriatrics</i> , 2020, 20, 258.	1.1	33
94	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer's disease. <i>Translational Psychiatry</i> , 2019, 9, 55.	2.4	32
95	Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 639-651.	1.2	32
96	The Arctic amyloid- β precursor protein (A β PP) mutation results in distinct plaques and accumulation of N- and C-truncated A β . <i>Neurobiology of Aging</i> , 2012, 33, 1010.e1-1010.e13.	1.5	31
97	Rapid amyloid- β oligomer and protofibril accumulation in traumatic brain injury. <i>Brain Pathology</i> , 2018, 28, 451-462.	2.1	31
98	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	4.5	31
99	Deposition of C-terminally truncated A β species A β 37 and A β 39 in Alzheimer's disease and transgenic mouse models. <i>Acta Neuropathologica Communications</i> , 2016, 4, 24.	2.4	29
100	Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology. <i>Neuropharmacology</i> , 2018, 128, 482-491.	2.0	29
101	Extracellular vesicles from amyloid- β exposed cell cultures induce severe dysfunction in cortical neurons. <i>Scientific Reports</i> , 2020, 10, 19656.	1.6	28
102	Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 71, S75-S83.	1.2	27
103	Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimer's Disease Patients Alter Calcium Homeostasis. <i>PLoS ONE</i> , 2013, 8, e74203.	1.1	26
104	Cystatin C Levels are Positively Correlated with both A β 42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 471-478.	1.2	25
105	A β 38 in the Brains of Patients with Sporadic and Familial Alzheimer's Disease and Transgenic Mouse Models. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 871-881.	1.2	25
106	Low prevalence of APP duplications in Swedish and Finnish patients with early-onset Alzheimer's disease. <i>European Journal of Human Genetics</i> , 2008, 16, 171-175.	1.4	24
107	In Situ Proximity Ligation Assay Reveals Co-Localization of Alpha-Synuclein and SNARE Proteins in Murine Primary Neurons. <i>Frontiers in Neurology</i> , 2018, 9, 180.	1.1	24
108	ABBV-0805, a novel antibody selective for soluble aggregated β -synuclein, prolongs lifespan and prevents buildup of β -synuclein pathology in mouse models of Parkinson's disease. <i>Neurobiology of Disease</i> , 2021, 161, 105543.	2.1	24

#	ARTICLE	IF	CITATIONS
109	Genotyping of Apolipoprotein E : Comparative Evaluation of Different Protocols. <i>Current Protocols in Human Genetics</i> , 2003, 38, Unit9.14.	3.5	23
110	Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. <i>Translational Neurodegeneration</i> , 2020, 9, 27.	3.6	23
111	Leukocytes with chromosome Y loss have reduced abundance of the cell surface immunoprotein CD99. <i>Scientific Reports</i> , 2021, 11, 15160.	1.6	23
112	The Uppsala APP deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid β fibril formation. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	23
113	In vivo imaging of alpha-synuclein with antibody-based PET. <i>Neuropharmacology</i> , 2022, 208, 108985.	2.0	23
114	Off-pathway β -synuclein oligomers seem to alter β -synuclein turnover in a cell model but lack seeding capability in vivo. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 233-244.	1.4	22
115	Increased Levels of Extracellular Microvesicle Markers and Decreased Levels of Endocytic/Exocytic Proteins in the Alzheimer's Disease Brain. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1671-1686.	1.2	22
116	Decreased Proportion of Cytomegalovirus Specific CD8 T-Cells but No Signs of General Immunosenescence in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e77921.	1.1	21
117	Risk factors for subarachnoid haemorrhage: a nationwide cohort of 950 000 adults. <i>International Journal of Epidemiology</i> , 2019, 48, 2018-2025.	0.9	21
118	Decreased HHV-6 IgG in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 40.	1.1	20
119	Abundance of A β -like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 13.	4.4	19
120	Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1456-1470.	1.7	19
121	In vivo imaging of synaptic density with [11C]UCB-J PET in two mouse models of neurodegenerative disease. <i>NeuroImage</i> , 2021, 239, 118302.	2.1	19
122	Disordered proteins in dementia. <i>Annals of Medicine</i> , 2002, 34, 259-271.	1.5	18
123	Changes in secondary structure of β -synuclein during oligomerization induced by reactive aldehydes. <i>Biochemical and Biophysical Research Communications</i> , 2015, 464, 336-341.	1.0	18
124	Timed Up-and-Go Dual-Task Testing in the Assessment of Cognitive Function: A Mixed Methods Observational Study for Development of the UDDGait Protocol. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1715.	1.2	18
125	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 629-640.	1.2	18
126	Differential DNA Methylation of the Genes for Amyloid Precursor Protein, Tau, and Neurofilaments in Human Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2021, 38, 1679-1688.	1.7	18

#	ARTICLE	IF	CITATIONS
127	Phosphorylated $\hat{\pm}$ -synuclein in skin Schwann cells: a new biomarker for multiple system atrophy. <i>Brain</i> , 2023, 146, 1065-1074.	3.7	18
128	Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation. <i>Neurogenetics</i> , 2009, 10, 27-34.	0.7	16
129	Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathways. <i>Free Radical Biology and Medicine</i> , 2017, 110, 421-431.	1.3	16
130	Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer's disease variants: $\hat{\Delta}^2$ PParc and PSEN1E9. <i>Molecular Psychiatry</i> , 2021, 26, 5609-5619.	4.1	16
131	Engulfment adapter PTB domain containing 1 interacts with and affects processing of the amyloid- $\hat{2}$ precursor protein. <i>Neurobiology of Aging</i> , 2012, 33, 732-743.	1.5	14
132	Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's disease. <i>Acta Neuropathologica Communications</i> , 2021, 9, 46.	2.4	14
133	Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. <i>Open Heart</i> , 2021, 8, e001735.	0.9	14
134	Large-scale Plasma Protein Profiling of Incident Myocardial Infarction, Ischemic Stroke, and Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e023330.	1.6	14
135	CRISPR-Cas9 treatment partially restores amyloid- $\hat{2}$ 42/40 in human fibroblasts with the Alzheimer's disease PSEN1 M146L mutation. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 450-461.	2.3	13
136	Gelsolin co-occurs with Lewy bodies in vivo and accelerates $\hat{\pm}$ -synuclein aggregation in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2011, 412, 32-38.	1.0	12
137	Reduction of $\hat{\pm}$ SYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. <i>Pharmaceutics</i> , 2022, 14, 1412.	2.0	12
138	CALHM1 P86L polymorphism does not alter amyloid- $\hat{2}$ or tau in cerebrospinal fluid. <i>Neuroscience Letters</i> , 2010, 469, 265-267.	1.0	11
139	Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice. <i>Neurobiology of Aging</i> , 2021, 101, 207-220.	1.5	11
140	Novel Progranulin Mutation Detected in 2 Patients With FTLD. <i>Alzheimer Disease and Associated Disorders</i> , 2011, 25, 173-178.	0.6	10
141	Torque teno virus viral load is related to age, CMV infection and HLA type but not to Alzheimer's disease. <i>PLoS ONE</i> , 2020, 15, e0227670.	1.1	9
142	Reduced plasma desmosterol to cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 67-74.	1.2	8
143	567. CRISPR-Cas9 Mediated Gene Editing in a Monogenic Form of Alzheimer's Disease. <i>Molecular Therapy</i> , 2016, 24, S226-S227.	3.7	8
144	Mapping of Surface-Exposed Epitopes of In Vitro and In Vivo Aggregated Species of Alpha-Synuclein. <i>Cellular and Molecular Neurobiology</i> , 2017, 37, 1217-1226.	1.7	8

#	ARTICLE	IF	CITATIONS
145	Dual-Task Tests Predict Conversion to Dementia—A Prospective Memory-Clinic-Based Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8129.	1.2	8
146	Visualization of early oligomeric α -synuclein pathology and its impact on the dopaminergic system in the (Thy1) ^{ΔE4} [A30P] α -syn transgenic mouse model. <i>Journal of Neuroscience Research</i> , 2021, 99, 2525-2539.	1.3	8
147	Modeling Parkinson's disease-related symptoms in alpha-synuclein overexpressing mice. <i>Brain and Behavior</i> , 2022, 12, .	1.0	8
148	Glycosylation profiling of selected proteins in cerebrospinal fluid from Alzheimer's disease and healthy subjects. <i>Analytical Methods</i> , 2019, 11, 3331-3340.	1.3	7
149	Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease. <i>Journal of Neuroimmunology</i> , 2019, 332, 31-36.	1.1	7
150	Mutation analysis of disease causing genes in patients with early onset or familial forms of Alzheimer's disease and frontotemporal dementia. <i>BMC Genomics</i> , 2022, 23, 99.	1.2	7
151	Micellar extraction possesses a new advantage for the analysis of Alzheimer's disease brain proteome. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 1041-1057.	1.9	6
152	Life-Time Covariation of Major Cardiovascular Diseases. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e002963.	1.6	5
153	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 22.	3.0	5
154	Generation and Characterization of Stable α -Synuclein Oligomers. <i>Methods in Molecular Biology</i> , 2018, 1779, 61-71.	0.4	3
155	Self-reported difficulty initiating sleep and early morning awakenings are associated with nocturnal diastolic non-dipping in older white Swedish men. <i>Scientific Reports</i> , 2020, 10, 13355.	1.6	2
156	Lack of fibrillar amyloid plaques but hypometabolism and astrogliosis in autosomal dominant variant A β PParc Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5471-5471.	4.1	0